Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
waveLINE-003: Zilovertamab Vedotin + Standard of Care in rrDLBCL
NCT05139017Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2022
- Primary completion
- Sep 2027
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of zilovertamab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by Merck & Co.. Started Jan 2022; status: recruiting.
02
Drugs
zilovertamab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05139017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05139017.